As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

A major new study has highlighted significant health risks associated with popular weight loss injections such as Ozempic, Wegovy, and Mounjaro. The research involved over two million patients and found that those using these medications have double the risk of developing pancreatitis – a potentially life-threatening inflammation of the pancreas.

Recent research reveals that weight-loss injections reduce the risk of 42 health conditions in people with diabetes, potentially paving the way for broader treatments.

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected but contain surprises, too.

Obesity expert Dr. Naomi Parrella of Rush University joins Marie Saavedra to talk about the new study and the impact for patients.

A major study involving two million people has unveiled surprising effects of weight-loss drugs like Ozempic and Wegovy. While originally designed to treat type 2 diabetes, these medications have been linked to improved heart health fewer infections,

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,

Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as substance abuse, psychosis, infections and even dementia. But these drugs also come with risks that shouldn't be overlooked,